Fabio Volterra

788 total citations
8 papers, 109 citations indexed

About

Fabio Volterra is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Fabio Volterra has authored 8 papers receiving a total of 109 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 2 papers in Surgery. Recurrent topics in Fabio Volterra's work include Acute Myeloid Leukemia Research (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Genetic factors in colorectal cancer (2 papers). Fabio Volterra is often cited by papers focused on Acute Myeloid Leukemia Research (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Genetic factors in colorectal cancer (2 papers). Fabio Volterra collaborates with scholars based in United States. Fabio Volterra's co-authors include Anthony Hoffman, Scott Wadler, Sanjay Goel, Sridhar Mani, Harold J. Burstein, Mark H. Einstein, Meghna Samant, C. J. Fabian, Gary L. Goldberg and Abbie L. Fields and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Investigational New Drugs.

In The Last Decade

Fabio Volterra

7 papers receiving 105 citations

Peers

Countries citing papers authored by Fabio Volterra

Since Specialization

Citations

This map shows the geographic impact of Fabio Volterra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabio Volterra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabio Volterra more than expected).

Fields of papers citing papers by Fabio Volterra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabio Volterra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabio Volterra. The network helps show where Fabio Volterra may publish in the future.

Co-authorship network of co-authors of Fabio Volterra

This figure shows the co-authorship network connecting the top 25 collaborators of Fabio Volterra. A scholar is included among the top collaborators of Fabio Volterra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabio Volterra. Fabio Volterra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who failed either abiraterone (Abi) or enzalutamide (Enza) 2019 ·Annals of Oncology ·Nicholas J. Vogelzang, Nashat Gabrail, Zafar Malik, Fabio Volterra, Luke T. Nordquist, Richard Levin, (unknown), (unknown)	1
2	SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer 2010 ·Annals of Oncology ·(unknown), (unknown), Taral Patel, (unknown), C. J. Fabian, Mark Kozloff, (unknown), Fabio Volterra, Hema Parmar, Meghna Samant, Harold J. Burstein	37
3	Phase I trial of CPI-613, a lipoic acid analog, and gemcitabine in patients with advanced solid tumors. 2010 ·Journal of Clinical Oncology ·Avi S. Retter, (unknown), (unknown), Eric A. Hoffman, Fabio Volterra, Anthony Hoffman, (unknown), (unknown)	1
4	Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T) 2007 ·Journal of Clinical Oncology ·(unknown), Leslie Rodgers Laufman, Khaled W. Jabboury, Mansoor N. Saleh, (unknown), Fabio Volterra, Jamie Arnott, (unknown), Carolyn Sidor, (unknown)	2
5	A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers 2005 ·Investigational New Drugs ·Sanjay Goel, Kavita Desai, (unknown), Scott Wadler, Gary L. Goldberg, Abbie L. Fields, Mark H. Einstein, Fabio Volterra, (unknown), (unknown), Sridhar Mani	1
6	A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers 2005 ·Investigational New Drugs ·Sanjay Goel, Kavita Desai, (unknown), Scott Wadler, Gary L. Goldberg, Abbie L. Fields, Mark H. Einstein, Fabio Volterra, (unknown), (unknown), Sridhar Mani	31
7	A Phase II Study of Rebeccamycin Analog NSC 655649 in Patients with Metastatic Colorectal Cancer 2003 ·Investigational New Drugs ·Sanjay Goel, Scott Wadler, Anthony Hoffman, Fabio Volterra, Cheryl H. Baker, (unknown), Percy Ivy, (unknown), Sridhar Mani	19
8	Intracaval and Intracardiac Metastatic Nonseminomatous Germ Cell Tumor: A Rare Cause of Hemolytic Anemia and Thrombocytopenia 2002 ·Cancer Investigation ·(unknown), Anthony Hoffman, Fabio Volterra, (unknown), (unknown)	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact